Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

Berger Montague PC announced an investigation into potential breaches of fiduciary duty by ADMA Biologics' board of directors. The announcement introduces governance and litigation risk for the biotech company, though the release provides no allegations, financial damages, or regulatory action details.